Earnings Release • Jun 17, 2013
Earnings Release
Open in ViewerOpens in native device viewer
Fresenius Medical Care is the world's largest integrated provider of products and services for dialysis, a blood-filtering therapy replacing vital kidney functions for patients suffering from chronic kidney failure. Through its network of around 3,200 dialysis clinics in more than 40 countries, Fresenius Medical Care provides dialysis treatments to around 262,000 patients. With more than 40 production sites around the globe, the company is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.
Our long-term strategy aims at sustainably increasing shareholder value. We focus our business activities on our patients' health and hence on the quality of treatment with the objective of improving their quality of life and raising their life expectancy.
As our previous growth strategy GOAL 13 comes to a close in 2013, we intend to set new goals in the current financial year that will allow us to maintain our outstanding market position and to be successful in the dialysis market. Basically we will continue along our growth paths in the future:
| Net revenue | \$ 3,464 million |
+7% |
|---|---|---|
| Operating income (EBIT) | \$ 493 million |
-2% |
| Net income1 | \$ 225 million |
-39% |
| Earnings per share | \$ 0.74 |
-40% |
| Total assets2 | \$ 22,140 million |
|
| Operating cash flow | \$ 315 million |
| Net revenue | > \$14.6 billion |
|---|---|
| Net income1 | \$1.1 billion – \$1.2 billion |
| Leverage ratio (Debt/EBITDA) | ≤ 3.0 |
| Capital expenditures | ~ \$700 million |
| Acquisitions | ~ \$300 million |
Dr. Emanuele Gatti Rolf A. Classon
Dr. Olaf Schermeier
1 attributable to shareholders of Fresenius Medical Care AG & Co. KGaA 2 as of March 31, 2013
Rice Powell (Chairman) Dr. Gerd Krick (Chairman)
| Ordinary shares | Preference shares |
|---|---|
| FME | FME3 |
| FMS | FMS/P |
| FMEG.DE / FMEG.F | FMEG_p.DE / FMEG_p.F |
| FME GY | FME3 GY |
| 578 580 | 578 583 |
| DE 0005785802 | DE 0005785836 |
| 358029106 | 358029205 |
| Amount in million | Coupon % | Maturity | |
|---|---|---|---|
| Credit Agreement Revolver | ~\$ 1,250 | October 30, 2017 | |
| Credit Agreement Term Loan A | \$ 2,6001 | October 30, 2017 | |
| Senior Notes 2010 - 2016 | € 250 | 5.50% | July 15, 2016 |
| Senior Notes 2011 - 2016 | € 100 | 3-month-Euribor +3.50% | Oct. 15, 2016 |
| Senior Notes 2007 - 2017 | \$ 500 | 6.875% | July 15, 2017 |
| Senior Notes 2011 - 2018 | \$ 400 | 6.50% | September 15, 2018 |
| Senior Notes 2011 - 2018 | € 400 | 6.50% | September 15, 2018 |
| Senior Notes 2012 - 2019 | \$ 800 | 5.625% | July 31, 2019 |
| Senior Notes 2012 - 2019 | € 250 | 5.25% | July 31, 2019 |
| Senior Notes 2011 - 2021 | \$ 650 | 5.75% | February 15, 2021 |
| Senior Notes 2011 - 2021 | € 300 | 5.25% | February 15, 2021 |
| Senior Notes 2012 - 2022 | \$ 700 | 5.875% | January 31, 2022 |
| Notes (Schuldscheindarlehen) 2009 - 2014 | € 451 | October 27, 2014 | |
| Accounts Receivable Facility | \$ 800 | July 31, 2014 |
Capital Structure Contacts
1 at the beginning before amortisation
2 Subject to the approval of the Annual General Meeting
| Event | Date |
|---|---|
| Report on first quarter 2013: | |
| Quarterly Report: | May 31, 2013 |
| Annual General Meeting 2013: | May 16, 2013 |
| Payment of dividend2 : |
May 17, 2013 |
| Report on second quarter : | July 30, 2013 |
| Report on Third Quarter 2013: | November 5, 2013 |
| Fresenius Medical Care AG & Co. KGaA Else-Kröner-Straße 1 |
Investor Relations & Corporate Communications 61352 Bad Homburg |
|---|---|
| Oliver Maier Senior Vice President, Head of IR & CC |
P:+49(0)6172-609-2525 F:+49(0)6172-609-2301 |
| Gerrit Jost Vice President |
P:+49(0)6172-609-5216 |
| North America Terry L. Morris Vice President |
P:+1-800-948-2538 F: +1-615-345-5605 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.